Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
|Shares Outstanding||EPS||-3.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-15.12|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-30.07%||ROE||-120.74%||ROI|
|Current Ratio||7.63||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.46|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||35.07 M||Cash From Investing Activities||6.1 M||Cash From Operating Activities||-13.31 M||Gross Profit|
|Net Profit||-17.24 M||Operating Profit||-19.64 M||Total Assets||195.2 M||Total Current Assets||170.96 M|
|Total Current Liabilities||22.39 M||Total Debt||124.19 M||Total Liabilities||146.58 M||Total Revenue|
|High 52 week||73.9||Low 52 week||33||Last close||40.18||Last change||0.35%|
|RSI||24.79||Average true range||1.98||Beta||1.35||Volume||623.98 K|
|Simple moving average 20 days||-6.56%||Simple moving average 50 days||-1.32%||Simple moving average 200 days||-25.12%|
|Performance Week||-3.76%||Performance Month||-9.77%||Performance Quart||-2.12%||Performance Half||-35.04%|
|Performance Year||-23.54%||Performance Year-to-date||11.3%||Volatility daily||2.54%||Volatility weekly||5.68%|
|Volatility monthly||11.64%||Volatility yearly||40.31%||Relative Volume||235.1%||Average Volume||612.54 K|
|New High||New Low|
2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma
2019-03-12 18:30:00 | Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
2019-03-12 18:20:00 | Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ netarsudil and latanoprost ophthalmic solution 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
2019-03-07 08:13:36 | Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years
2019-03-05 08:02:09 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-03-05 07:30:00 | Aerie Pharmaceuticals to Present at Two Investor Conferences in March
2019-03-01 08:25:00 | New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019
2019-02-26 20:40:37 | Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT
2019-02-26 10:34:03 | Aerie AERI Q4 Earnings Miss, Rhopressa Gains Traction
2019-02-25 21:13:52 | Aerie Pharmaceuticals Inc AERI Q4 2018 Earnings Conference Call Transcript
2019-02-22 13:55:45 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
2019-02-08 08:04:08 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-02-05 14:25:56 | Mizuho's 9 Best Biotech Stocks to Buy for 2019
2019-02-04 04:56:09 | Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?
2019-01-18 09:10:02 | Aerie's AERI Eye Care Candidate to Enter Clinical Studies
2019-01-17 11:47:27 | A Spotlight On Aerie Pharmaceuticals, Inc.’s NASDAQ:AERI Fundamentals
2019-01-17 08:06:04 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-01-17 05:14:00 | How to spot risky biotech companies and six to avoid now
2019-01-09 08:05:38 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-01-07 16:57:09 | Aerie's Rhopressa Succeeds in Study on Japanese Patients
2018-12-13 08:06:41 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2018-12-12 14:48:07 | Aerie Division's Prospects Have Analysts Bullish On American Eagle
2018-12-12 00:58:06 | Hedge Funds Are Selling Aerie Pharmaceuticals Inc AERI
2018-12-06 08:46:01 | Should You Get Rid of Aerie Pharmaceuticals AERI Now?
2018-12-04 07:20:00 | Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
2018-11-29 08:06:45 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2018-11-24 08:05:44 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2018-11-22 08:05:52 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2018-11-19 14:08:03 | Mariko Gordon's Top 5 New Buys
2018-11-13 06:26:11 | Aerie Pharmaceuticals AERI: Moving Average Crossover Alert
2018-11-09 08:04:50 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2018-11-08 16:05:09 | Aerie AERI Q3 Earnings Miss, Rhopressa Gains Traction
2018-11-07 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
2018-11-07 01:30:11 | Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT
2018-11-06 17:55:10 | Aerie Pharmaceuticals AERI Reports Q3 Loss, Tops Revenue Estimates
2018-11-06 16:50:39 | Aerie: 3Q Earnings Snapshot
2018-10-25 08:30:00 | Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Developments
2018-10-24 08:11:09 | Aerie completes Durham HQ expansion
2018-10-18 12:43:54 | Is There An Opportunity With Aerie Pharmaceuticals Inc’s NASDAQ:AERI 48% Undervaluation?
2018-10-16 08:03:52 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.